severe chronic obstructive pulmonary disease

Lupin Launches Luforbec 100/6 μg pMDI, first branded generic alternative to Fostair 100/6 μg pMDI for treatment of Asthma & COPD, in the UK

New Delhi, September 12, 2021: Lupin Healthcare (UK) Limited, wholly-owned subsidiary of global pharma major Lupin Limited (Lupin), today announced that…

3 years ago